Patients diagnosed with ALS according to the revised EI Escorial diagnostic criteria of the World Federation of Neurology (WFN) in 1994 (revised in 1998). To diagnose ALS, you need to: 1. Clinical, electrophysiological or neuropathological examination with signs of LMN (lower motor neuron) degeneration
Conditions
Interventions
Ciprofloxacin and Celecoxib combination group:None
Non-combination group:None
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1 18 to 75 years old; 2. Gender: unlimited; 3.From April 2014 to April 2023, he/she was diagnosed with amyotrophic lateral sclerosis at Nanfang Hospital of Southern Medical University; 4.During his visit to our hospital, he/she was treated with ciprofloxacin for concomitant genitourinary infections, respiratory tract infections or gastrointestinal infections, and was treated with celecoxib for pain caused by various causes. 5.Disease duration less than 3 years prior to diagnosis after the first onset of ALS symptoms
Exclusion criteria
Exclusion criteria: 1.Patients with other neurological diseases with symptoms similar to ALS that affect the results of the study, such as cervical myelopathy, syringomyelia, spinal cord and brainstem tumors, Hirayama disease, multifocal motor neuropathy, multiple sclerosis, Guillain-Barre syndrome, Parkinson's disease and dementia, etc. 2.Aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, glutamyl transpeptidase or glutamate dehydrogenase > 1.5 times the upper limit of the normal reference value, or serum creatinine (Scr) > the upper limit of the normal reference value; 3.Any medically unstable condition that is considered clinically significant by the investigator, including but not limited to the presence of abnormalities such as cardiovascular and cerebrovascular, hepatic and renal dysfunction, endocrine system, psychiatric system or nervous system that in the opinion of the investigator will interfere with the interpretation of the overall safety or efficacy of the study; 4.Patients with ALS who are judged by the investigator to be unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decline rate of the ALSFRS-R score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fine typing of B lymphocytes;cytokines;Fine typing of T lymphocytes;ALSFRS-R score; | — |
Countries
China
Contacts
Public ContactJiang Haishan
Southern Medical University Southern Hospital
Outcome results
None listed